Discovery-to-Clinic (05/18/2026 00: 00
HYFT
Published on 05/18/2026 at 08:17 am EDT
Discovery-to-Clinic
Clinical-Stage Drug Candidates and Programs Originating from MindWalk Discovery Platforms
MindWalk Holdings Corp. (NASDAQ: HYFT) • May 2026
Formerly ImmunoPrecise Antibodies Ltd.
A Note on Naming
MindWalk Holdings Corp. (NASDAQ: HYFT) was formerly known as ImmunoPrecise Antibodies Inc. (NASDAQ: IPA). All publications, patents, and partner references in this document cite the ImmunoPrecise Antibodies name, which was the company's identity during the period these discovery programs were executed (2001-2025). For clarity, these historical site names are referred to herein as "MindWalk".
MindWalk's role across all programs cited is as the discovery partner. Programs where the Company's role was minor, for example, research-grade optimization and manufacturing are not included. The clinical assets, intellectual property, development decisions, and commercial rights are wholly owned by the partner companies. These case studies demonstrate that antibodies originating from MindWalk's discovery engine have a documented track record of advancing into clinical development. They do not represent a clinical pipeline owned by MindWalk.
Executive Summary
MindWalk operates global antibody discovery sites that have collectively produced over 400 peer-reviewed publications and patents spanning two decades. This publication record documents an underappreciated asset: MindWalk-discovered antibodies are the discovery-stage origin of clinical-stage drug programs and high-value partnerships across publicly traded biotechs, major pharma, private companies, academic medical centers, and disease-focused foundations - programs that are wholly owned and advanced by those partners.
This analysis identifies 20 distinct partner-owned drug candidates and therapeutic programs where MindWalk identified and discovered the candidates. Ten partner programs with direct links to MindWalk-discovered antibodies are in active clinical trials. The remainder span major pharma collaborations (Sanofi Pasteur, Janssen/J&J), foundation-funded research (Michael J Fox Foundation), academic partnerships with clinical trajectories (University of Virginia, MidWestern University), and a diagnostic commercialization partnership (Perseus Science/ChemBio). The OncoResponse immuno-oncology programs (OR502, OR641) represent a notable expansion into the myeloid checkpoint space via IPA's B Cell Select® rabbit antibody platform. In every case, the clinical assets are wholly owned, advanced, and funded by the partner.
In every case, MindWalk discovered the antibody from which the downstream program was built. This places MindWalk at arguably the most critical decision point in drug development - the moment where target engagement is first demonstrated and the molecular series is born.
Discovery-to-Clinic Snapshot - Programs Originating from MindWalk Discovery
Active partner clinical programs (Phase 1-3)
10
Total drug candidates / programs identified
21+
Partner companies & institutions
17+ (public, private, pharma, academic, foundations)
Major pharma relationships
Sanofi Pasteur, Janssen/J&J (Crucell)
MindWalk co-authored publications (PubMed)
8 papers, 20 unique scientists
Total publication track record
400 publications (2001-2025)
Discovery Partner Clinical Programs
The following discovery programs at biotech and pharma partners were led by MindWalk under the ImmunoPrecise name.
Phase 3: ANX005 - Annexon Biosciences
Target
Complement C1q
Indication
Guillain-Barré Syndrome (GBS)
Clinical Status
Active - GALLOP Phase 3 trial. FDA Breakthrough Therapy designation.
MindWalk discovered lead antibodies 1C7, 2A1, 3A2, 5A3. The clinical lead, ANX005, inhibits the classical complement pathway and has demonstrated significant clinical benefit in GBS patients, earning FDA Breakthrough Therapy designation. ANX005 is wholly owned, developed, and advanced by Annexon Biosciences.
Phase 3: ARGX-119 - argenx (NASDAQ: ARGX)
Target
MuSK (muscle-specific kinase)
Indication
Congenital Myasthenic Syndrome (CMS)
Clinical Status
Phase 2/3 planned for 2026. First-in-class MuSK agonist antibody.
argenx selected and humanized ARGX-119 from a panel of anti-MuSK lead antibodies discovered at MindWalk. ARGX-119 a first-in-class agonist antibody that enhances neuromuscular junction signaling. Three publications spanning multiple years document the discovery campaign. ARGX-119 is wholly owned and developed by argenx; MindWalk's contribution was discovery-stage only.
Also: ARGX-119 is an agonist antibody for human MuSK that reverses disease relapse (Peer-reviewed, Science Translational Medicine) (2024)
Phase 2: Vudalimab (XmAb20717) - Xencor (NASDAQ: XNCR)
Target
PD-1 × CTLA-4 bispecific
Indication
Metastatic castration-resistant prostate cancer; solid tumors
Clinical Status
Active - Phase 2 ongoing across multiple solid tumor indications.
The anti-PD-1 antibody panel was generated by MindWalk and feeds Xencor's bispecific antibody platform. Vudalimab is the lead clinical asset. The same legacy MindWalk-discovered PD-1 arm is used across multiple Xencor programs (XmAb306, XmAb808, and others). The Xencor clinical programs
(vudalimab, XmAb306, XmAb808, and others) are wholly owned by Xencor; MindWalk's contribution
was discovery-stage hybridoma generation only.
Phase 2: CIT-013 - Citryll BV
Target
Citrullinated histones H2A/H4 (NET formation)
Indication
Rheumatoid arthritis; hidradenitis suppurativa; NET-mediated inflammatory diseases
Clinical Status
Active - Phase 2a RA (NCT06567470), Phase 2a HS (NCT06993233), Phase 2 PET imaging (NCT07147959), Phase 1 SC dosing (NCT07499908).
CIT-013 is a therapeutic anti-citrullinated protein antibody (tACPA) that inhibits neutrophil extracellular trap (NET) formation. The therapeutic inventors also produced the gold-standard anti-CCP diagnostic test for rheumatoid arthritis, at MindWalk. CIT-013 is wholly owned, developed, and advanced by Citryll BV; MindWalk holds no ownership in the asset.
Citryll's preclinical program demonstrated broad efficacy across inflammatory arthritis, pulmonary fibrosis, inflammatory bowel disease, and sepsis models. CIT-013 targets citrulline residues in the N-termini of histones H2A and H4 generated during NET release, suppressing NETosis and promoting NET uptake by macrophages.
Phase 1b: PMN310 - ProMIS Neurosciences
Target
Aβ oligomers (misfolded)
Indication
Alzheimer's Disease
Clinical Status
Active - Phase 1b (NCT05948124). Data expected 2026.
Antibodies that selectively bind toxic misfolded protein conformations were discovered under the ImmunoPrecise name. The conformation-selective approach differentiates PMN310 from earlier anti-amyloid antibodies that target all forms of Aβ. PMN310 is wholly owned and developed by ProMIS Neurosciences; MindWalk's contribution was discovery-stage only.
Phase 1: XmAb306 - Xencor (NASDAQ: XNCR)
Target
IL-15/IL-15Rα × PD-1 bispecific
Indication
Solid tumors / Immuno-oncology
Clinical Status
Active - Phase 1 (NCT05275439).
Anti-PD-1 antibodies discovered by MindWalk were incorporated into Xencor's IL-15 cytokine-armed bispecific platform. XmAb306 combines T-cell stimulation with checkpoint blockade in a single molecule.
fragments (US Patent Application) (2023)
Phase 1: CLN-619 - Cullinan Oncology (NASDAQ: CGEM)
Target
MICA/MICB (NKG2D ligands)
Indication
Solid tumors
Clinical Status
Active - Phase 1 (NCT05615493).
The anti-MICA/MICB antibody panel was discovered and generated by MindWalk. Cullinan acquired Novelogics to develop CLN-619, which stabilizes NKG2D ligands on tumor cells to enhance natural killer cell killing. CLN-619 is wholly owned by Cullinan Oncology; MindWalk's contribution was discovery-stage antibody work only.
Phase 1: XmAb808 - Xencor (NASDAQ: XNCR)
Target
PD-L1 × CD28 bispecific
Indication
Solid tumors
Clinical Status
Active - Phase 1.
MindWalk discovered the antibody used in Xencor's CD28 co-stimulatory bispecific, combining checkpoint modulation with T-cell co-stimulation.
Phase 1/2: OR502 - OncoResponse
Target
LILRB2 (ILT4)
Indication
Advanced solid tumors (immuno-oncology)
Clinical Status
Active - Phase 1/2 clinical trial. Phase 1 data (SITC 2024) showed 65% disease control rate (2 PR + 9 SD, N=17).
OR502 is a humanized IgG1 antibody targeting LILRB2 (ILT4), an inhibitory receptor on immunosuppressive myeloid cells. The parental rabbit monoclonal antibody was generated using
ImmunoPrecise's proprietary B Cell Select® platform. OR502 blocks LILRB2 interaction with HLA class I ligands, relieving myeloid-mediated immune suppression and enhancing both innate and adaptive anti-tumor immunity. Preclinical data demonstrated best-in-class activity versus benchmark anti-LILRB2 antibodies, including superior enhancement of IFNγ production and T-cell function. OR502 significantly enhanced the activity of pembrolizumab in combination studies. OR502 is wholly owned, developed, and advanced by OncoResponse; MindWalk's contribution was discovery-stage rabbit B cell antibody generation only.
Preclinical: OR641 - OncoResponse
Target
LILRB1 × LILRB2 (dual antagonist)
Indication
Solid tumors (immuno-oncology)
Clinical Status
IND-enabling studies. Cell line development completed.
OR641 is a humanized dual antagonist antibody derived from rabbit B cells immunized with LILRB2 protein, generated using ImmunoPrecise's B Cell Select® platform. OR641 binds both LILRB1 (ILT2) and LILRB2 (ILT4), blocking their interactions with HLA class I ligands. Dual antagonism restores both innate and adaptive immune responses - a strategy to enhance checkpoint inhibitor efficacy. OR641 demonstrated best-in-class activity: promoting Th1-like innate immunity, enhancing macrophage phagocytosis of HLA-G+ tumor cells, rescuing NK cell cytotoxicity, and restoring exhausted T-cell function. Half-life of 10 days in humanized FcRn mice. OR641 is wholly owned by OncoResponse; MindWalk's contribution was discovery-stage only.
Phase 1 (Disc.): LAVA-1207 - Lava Therapeutics
Target
Vδ2-TCR × tumor targets
Indication
Metastatic castration-resistant prostate cancer
Clinical Status
Discontinued December 2024 - Lava restructured.
MindWalk provided VHH and protein expression support for Lava's γδ T-cell engager platform. LAVA-1207 was the lead program. LAVA-1207 was wholly owned by Lava Therapeutics; MindWalk's contribution was discovery- and expression-stage support only.
Major Pharma & Foundation Non-Therapeutic Biologics Programs
Beyond the clinical-stage biotech partnerships, MindWalk's publication record documents discovery work for major pharmaceutical companies, foundations, and diagnostics firms. These relationships signal the platform's credibility and breadth.
Sanofi Pasteur - Vaccine Development
Partner
Sanofi Pasteur Ltd. (Canada)
Program
Immunogenic polypeptides and monoclonal antibodies
Discovery Method
Hybridoma (MindWalk Canada)
Significance
Discovery collaboration with one of the world's largest vaccine manufacturers
MindWalk generated antibodies for Sanofi Pasteur's vaccine research program, documented in a jointly cited patent. Sanofi Pasteur is among the most selective buyers of external discovery capability in the vaccine space.
Janssen Vaccines (Johnson & Johnson) - Vaccine Analytics
Partner
Janssen Vaccines & Prevention (Crucell), a J&J subsidiary
Program
Capillary electrophoresis applications for viral vaccine analysis
Significance
Analytical support for J&J's vaccine platform using MindWalk-generated antibodies
MindWalk-generated hybridoma antibodies were used in Janssen's vaccine quality control analytics, supporting 16 distinct capillary electrophoresis applications. This illustrates how IPA antibodies become embedded in a major pharma partner's analytical workflow.
Michael J. Fox Foundation - Parkinson's Disease Research Tools
Partner
The Michael J. Fox Foundation for Parkinson's Research
Program
Phospho-ubiquitin (p-S65-Ub) antibodies for PINK1-PRKN signaling
Clinical Relevance
PINK1/PRKN pathway now targeted by AbbVie (ABBV-1088, Phase 1) and Mission Therapeutics (MTX325, Phase 1)
MindWalk co-authored this work. The MindWalk-discovered phospho-ubiquitin antibodies are enabling tools for one of the most active areas in Parkinson's drug development. Multiple clinical programs (AbbVie's ABBV-1088, Mission Therapeutics' MTX325) now target the PINK1/PRKN mitophagy pathway that these antibodies monitor.
Perseus Science / ChemBio - Point-of-Care TBI Diagnostic
Partner
Perseus Science Group LLC (formerly ChemBio Diagnostics)
Program
PKC-gamma blood biomarker for traumatic brain injury / concussion
Status
Development partnership for point-of-care concussion test. FDA pathway.
MindWalk generated the rabbit B cell-derived antibodies targeting PKC-gamma, a CNS injury biomarker. Perseus Science partnered with ChemBio Diagnostics to develop a rapid point-of-care concussion test using MindWalk-derived antibodies on ChemBio's DPP diagnostic platform. The combination of a patented biomarker with IPA-generated antibodies in a commercial diagnostic illustrates additional value creation experience in the diagnostic field.
Academic & Preclinical Programs
The following programs are at earlier stages but demonstrate MindWalk's reach into novel therapeutic
targets and academic medical centers.
Program
Partner
Target
Indication
Note
Anti-SAS1B ADC
University of Virginia
SAS1B (cancer-oocyte antigen)
Pancreatic cancer, uterine tumors
ADC shown to kill cancer cells at 0.01-0.1 µg/mL. SAS1B
expressed in 68% of pancreatic cancers. IPA scientist Andra Li co-authored.
Anti-ASPH mAb / ADC
MidWestern University
Aspartyl β-hydroxylase (ASPH)
Pancreatic, liver, biliary cancer
ASPH is a validated cancer target. ADC and small molecule approaches in preclinical development.
Anti-TDP-43 mAb
UBC / ProMIS Neurosciences
TDP-43 (misfolded)
ALS /
Frontotemporal Dementia
Conformation-selective antibodies for misfolded TDP-
43. Relevant to MindWalk's
own TDP-43 pipeline interest.
Anti-CLPTM1
Genagon Therapeutics (Sweden)
CLPTM1 (novel tumor antigen)
Oncology (solid tumors)
Novel target discovered by Genagon. MindWalk generated the hybridoma panel.
Artenga MDC
Artenga Inc.
AAV2 capsid (microbubble conjugate)
CNS disorders (BBB crossing)
Antibodies for microbubble drug conjugate platform enabling blood-brain barrier penetration.
SerpinX AAT variant
SerpinX
α1-Antitrypsin (engineered serpin)
α1-Antitrypsin Deficiency (AATD)
AATD is a hot therapeutic area
- BEAM-302 (Beam), CTX460
(CRISPR Tx) and others now entering Phase 1.
IDEXX Veterinary Dx
IDEXX Laboratories (NASDAQ: IDXX)
Clusterin isoforms; tapeworm antigens
Veterinary diagnostics
Repeat commercial client. IDEXX has ~$40B market cap. Two separate IPA discovery campaigns documented.
References - Academic & Preclinical Programs
Co-Authored Publications
Beyond fee-for-service work, MindWalk scientists are named co-authors on peer-reviewed publications
- a meaningful signal that the company's contribution extends into genuine scientific collaboration. A PubMed affiliation search for "ImmunoPrecise" - the legacy name under which these papers were published - returns 13 publications with 23 unique MindWalk scientists as co-authors. An additional 5 publications carry ModiQuest B.V. (Oss) affiliations, connecting the legacy Netherlands antibody operations to the current MindWalk scientific network.
The standout is the 2024 SARS-CoV-2 multi-antibody paper in Biomedicines, where 21 of approximately 30 authors carry an ImmunoPrecise affiliation. This is company-led science, not a service acknowledgment. The ModiQuest papers feature Renato Chirivi and the late Jos Raats (formerly of MindWalk), whose tACPA work became CIT-013 (now in Phase 2).
Broad Epitope Coverage of Therapeutic Multi-Antibody Combinations Targeting SARS-CoV-2
Biomedicines (2024) • 21 IPA co-authors (Roodink, van Erp, Li, et al.)
Development and characterization of phospho-ubiquitin antibodies to monitor PINK1-PRKN signaling
Autophagy (2024) • Karima Pirani
Intratumoral injection of IL-12-encoding mRNA targeted to CSF1R and PD-L1
Mol. Therapy - Nucleic Acids (2023) • Sander M J van Duijnhoven
Shortened Hinge Design of Fab × sdAb-Fc Bispecific Antibodies Enhances Redirected T-Cell Killing
Biomolecules (2022) • Sander M J van Duijnhoven
Monoclonal antibody 7H2.2 binds the C-terminus of the cancer-oocyte antigen SAS1B
Acta Crystallographica D (2022) • Andra Li
Metformin alters H2A.Z dynamics and regulates androgen dependent prostate cancer progression
Oncotarget (2019) • Deanna Dryhurst
A Novel Sensitive Immunoassay Targeting 5-Methylthio-d-Xylofuranose-Lipoarabinomannan (TB diagnostics)
J. Clinical Microbiology (2018) • Andra Li
Engineering Elastin-Like Peptide-Based Nanoparticles displaying VHH for SARS-CoV-2 Neutralization
Biomacromolecules (2025) • Ilse Roodink
Therapeutic ACPA inhibits NET formation: a potential therapy for neutrophil-mediated inflammatory diseases
Cell. Mol. Immunol. (2020) • Renato Chirivi, Jos Raats [ModiQuest/Citryll]
Recombinant antibody against Trypanosoma cruzi from Chagas heart disease patients recognizes mammalian nervous system
EBioMedicine (2021) • Renato Chirivi, Jos Raats [ModiQuest]
Humanization of Murine Monoclonal anti-hTNF Antibody: The F10 Story
Molekuliarnaia Biologiia (2017) • Jos Raats, Renato Chirivi [ModiQuest]
In vivo phage display screening for tumor vascular targets in glioblastoma identifies a llama nanobody
Oncotarget (2016) • Ilse Roodink, Jos Raats [ModiQuest]
Control of organization and function of muscle and tendon by thrombospondin-4
Matrix Biology (2014) • Guido Jenniskens [ModiQuest Research BV]
Analytical Observations
This expanded analysis surfaces several points relevant to MindWalk's investment profile:
Methodology
This report was compiled from: (1) a systematic review of MindWalk's 400-publication internal tracker spanning 2001-2025 (published under the ImmunoPrecise and ModiQuest names); (2) PubMed affiliation searches for "ImmunoPrecise" to identify co-authored publications; (3) ClinicalTrials.gov, company press releases, SEC filings, and patent databases for current clinical status; (4) web research for partner company pipelines, FDA designations, and trial updates; and (5) filtering for discovery-only contributions, excluding manufacturing and protein expression work where IPA's role was purely production.
Clinical phase assignments reflect publicly available information as of April 2026. Trial statuses may change. This document does not constitute investment advice.
.
MindWalk Holdings Corp. (formerly ImmunoPrecise Antibodies) • CONFIDENTIAL • Page
Disclaimer
MindWalk Holdings Corp. published this content on May 18, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on May 18, 2026 at 12:16 UTC.